Clinical Laserthermia Systems 将来の成長

Future 基準チェック /26

Clinical Laserthermia Systems収益と収益がそれぞれ年間63.8%と51.9%増加すると予測されています。

主要情報

63.8%

収益成長率

n/a

EPS成長率

Medical Equipment 収益成長	36.9%
収益成長率	51.9%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	02 Nov 2024

今後の成長に関する最新情報

更新なし

Recent updates

We Think Clinical Laserthermia Systems (STO:CLS B) Needs To Drive Business Growth Carefully

Jan 03

Will Clinical Laserthermia Systems (STO:CLS B) Spend Its Cash Wisely?

Aug 26

Clinical Laserthermia Systems (STO:CLS B) Is Making Moderate Use Of Debt

Mar 01

業績と収益の成長予測

OM:CLS B - アナリストの将来予測と過去の財務データ ( )SEK Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	64	N/A	N/A	-9	1
12/31/2025	43	-25	-24	-20	1
12/31/2024	23	-51	-61	-56	1
9/30/2024	19	-64	-65	-59	N/A
6/30/2024	15	-68	-63	-59	N/A
3/31/2024	11	-71	-75	-72	N/A
12/31/2023	8	-80	-72	-66	N/A
9/30/2023	8	-63	-74	-70	N/A
6/30/2023	7	-77	-81	-78	N/A
3/31/2023	6	-78	-85	-82	N/A
12/31/2022	6	-71	-82	-82	N/A
9/30/2022	3	-81	-81	-81	N/A
6/30/2022	2	-63	-66	-66	N/A
3/31/2022	2	-68	-71	-71	N/A
12/31/2021	2	-64	-67	-66	N/A
9/30/2021	1	-60	-63	-63	N/A
6/30/2021	2	-57	-55	-55	N/A
3/31/2021	2	-47	-41	-41	N/A
12/31/2020	1	-58	-56	-55	N/A
9/30/2020	1	-58	-54	-53	N/A
6/30/2020	2	-57	-54	-54	N/A
3/31/2020	6	-54	-52	-52	N/A
12/31/2019	6	-43	-39	-39	N/A
9/30/2019	6	-38	-37	-36	N/A
6/30/2019	5	-37	-35	-34	N/A
3/31/2019	1	-41	-44	-43	N/A
12/31/2018	8	-33	-41	-39	N/A
9/30/2018	10	-28	-33	-31	N/A
6/30/2018	11	-24	N/A	-31	N/A
3/31/2018	12	-15	N/A	-24	N/A
12/31/2017	8	-21	N/A	-24	N/A
9/30/2017	8	-22	N/A	-29	N/A
6/30/2017	8	-26	N/A	-24	N/A
3/31/2017	6	-27	N/A	-23	N/A
12/31/2016	4	-27	N/A	-20	N/A
9/30/2016	1	-27	N/A	-19	N/A
6/30/2016	0	-23	N/A	-22	N/A
3/31/2016	0	-20	N/A	-17	N/A
12/31/2015	N/A	-17	N/A	-19	N/A
9/30/2015	0	-21	N/A	-21	N/A
6/30/2015	0	-20	N/A	-20	N/A
3/31/2015	0	-20	N/A	-19	N/A
12/31/2014	N/A	-18	N/A	-16	N/A
9/30/2014	0	-16	N/A	-18	N/A
6/30/2014	N/A	-16	N/A	-18	N/A
3/31/2014	N/A	-17	N/A	-17	N/A

アナリストによる今後の成長予測

収入対貯蓄率: CLS B今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: CLS B今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: CLS B今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: CLS Bの収益 ( 51.9% ) Swedish市場 ( -0% ) よりも速いペースで成長すると予測されています。

高い収益成長: CLS Bの収益 ( 51.9% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: CLS Bの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Clinical Laserthermia Systems 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Recent updates

New major risk - Share price stability

Third quarter 2024 earnings released

Clinical Laserthermia Systems AB (publ) Approves Board Appoints

Clinical Laserthermia Systems AB (Publ) Announces Board Resignations

Insufficient new directors

Second quarter 2024 earnings released

New major risk - Shareholder dilution

Clinical Laserthermia Systems AB (publ) Announces Completion of Clinical Study At Skane University Hospital

First quarter 2024 earnings released

New major risk - Share price stability

Clinical Laserthermia Systems AB (Pub) Announces Two Patients with Localized Prostate Cancer Have Been Safely Treated with the Tranberg Thermal Therapy System At the San Luigi Gonzaga University Hospital in Turin, Italy

Clinical Laserthermia Systems AB (publ) Announces CFO Changes

Clinical Laserthermia Systems AB (publ) Announces Publication of Preclinical Assessment of A Non-Cooled MR Thermometry-Based Neurosurgical Laser Therapy System

Full year 2023 earnings released: kr0.06 loss per share (vs kr0.85 loss in FY 2022)

Clinical Laserthermia Systems AB (publ) to Report Q2, 2024 Results on Aug 23, 2024

Clinical Laserthermia Systems AB (Publ) Files A New Patent Application for Expanded and Extended Protection of the Company's Technology for Laser-Based Tissue Ablation Until 2044

New major risk - Share price stability

Clinical Laserthermia Systems AB (publ) Receives Market Approval for Its TRANBERG Portfolio by HSA in Singapore and Initiates the Process of Commercialization in the Region

Clinical Laserthermia Systems AB (publ) Announces Members of the Nomination Committee Appointments

Clinical Laserthermia Systems AB (publ) Announces Executive Changes

Clinical Laserthermia Systems AB (publ) Announces First Patient was Safely Treated with CLS TRANBERG® Thermal Therapy system for laser ablation of Prostate Cancer

High number of new directors

Third quarter 2023 earnings released

Clinical Laserthermia Systems AB (publ) Announces Enrollment Completion of Initial Phase and Extension of Clinical Trial at Radboud University Medical Center

Clinical Laserthermia Systems AB (publ) Announces Resignation of Rolf Ho Bornschein as CFO

Second quarter 2023 earnings released

Clinical Laserthermia Systems AB (publ), Annual General Meeting, Jun 29, 2023

First quarter 2023 earnings released

Clinical Laserthermia Systems AB Appoints Jimmy Johansson as Executive VP Operations

Full year 2022 earnings: EPS and revenues miss analyst expectations

Clinical Laserthermia Systems AB (Publ) Announces First Glioblastoma Patient Treated with the Mr-Guided Laser Interstitial Thermal Therapy (MRg LITT) in the Study At Skåne University Hospital

Third quarter 2022 earnings released

High number of new and inexperienced directors

BioStock Studio Announces FDA clearance

Clinical Laserthermia Systems Receives 510(K) Clearance for Its MR Guided Laser Ablation System in Neurosurgery and Initiates Commercialization

Second quarter 2022 earnings released

Clinical Laserthermia Systems AB (publ) Appoints Rolf Ho Bornschein as the New CFO, Effective October 1, 2022 Replacing Lars-Erik Eriksson

Clinical Laserthermia Systems AB (publ) to Report Fiscal Year 2022 Final Results on Feb 23, 2023

Clinical Laserthermia Systems AB (Publ) Appoints Dan J. Mogren as Permanent CEO

Clinical Laserthermia Systems AB's Subsidiary CLS Americas Announces First Patient Treated in Clinical Study Targeted MRI/ US Fusion Transperineal Laser Ablation of Low-To-Intermediate Risk Prostate Cancer

Clinical Laserthermia Systems AB (publ) Releases Ce-Marked New Version of Thermoguide™ Workstation for Use Also with Mri Scanners from GE Healthcare

Clinical Laserthermia Systems AB (Publ) Announces CEO Changes

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Clinical Laserthermia Systems AB (publ) Announces CEO Changes

We Think Clinical Laserthermia Systems (STO:CLS B) Needs To Drive Business Growth Carefully

Clinical Laserthermia Systems AB (publ) Files 510 (K) Application with the U.S. Food and Drug Administration for the Second Generation of TRANBERG®

Clinical Laserthermia Systems AB (Publ) Again Releases Tranberg® Sterile Disposable Products on the European Market and Enters into an Agreement with Two Additional Suppliers of Sterilization Services

Third quarter 2021 earnings released

Clinical Laserthermia Systems AB (Publ) to Present TRANBERG® Laser Thermal Therapy System and Latest Enhancements at the 73rd Congress of the German Society for Urology Conference

Will Clinical Laserthermia Systems (STO:CLS B) Spend Its Cash Wisely?

Second quarter 2021 earnings released

Clinical Laserthermia Systems AB (publ) and Toronto General Hospital Resume Clinical Trial for Prostate Cancer as Company Receives Approval for Updated Sterilization Process by Health Canada

Clinical Laserthermia Systems AB (publ) and University Hospital Magdeburg Obtains the Go for the Investigator Initiated Trial on Focal Laser Ablation Treatment of Localized Prostate Cancer, with the TRANBERG

First quarter 2021 earnings released

Clinical Laserthermia Systems (STO:CLS B) Is Making Moderate Use Of Debt

Full year 2020 earnings released: kr1.24 loss per share (vs kr1.25 loss in FY 2019)

New 90-day low: kr4.20

New 90-day low: kr4.44

New 90-day low: kr4.80

New 90-day low: kr6.28

Clinical Laserthermia Systems AB (Publ) and Toronto General Hospital Continue Clinical Trial Collaboration Regarding MRI-Guided Laser Ablation Treatment of Prostate Cancer

CLS Receives New CPT® Reimbursement Code Approval by American Medical Association for Ultrasound-Guided Focal Laser Ablation of Prostate Cancer

New 90-day low: kr6.68

Clinical Laserthermia Systems AB (Publ) and University Hospital Magdeburg Launch Clinical Trial Regarding Focal Laser Ablation Treatment of Localized Prostate Cancer

New 90-day low: kr6.93

First half earnings released

New 90-day high - kr9.72

New 90-day high - kr7.50

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘